Meghann has over 25 years of clinical and research experience in a broad variety of therapeutic indications, including Hematology/Oncology, Critical Care, Immunology, Women’s Health, Central Nervous System, Cardiology and Respiratory. As the Immune Mediated Inflammatory Disease (IMID) Therapeutic Area Strategy Lead for Worldwide Clinical Trials, Meghann lends her expertise to guide operational and therapeutic strategies that facilitate successful study outcomes.
In prior roles, Meghann was the internal hematology expert within a large CRO for malignant and non-malignant hematology and rare diseases (Phases I-IV). She was also the specialty team leader for Early Phase Hematology/Oncology and was responsible for the development and strategic evaluation and risk analysis of studies, programs and global staff within the Early Phase Hematology/Oncology team.
Meghann’s clinical trial experience includes, but is not limited to, ARDs, Cardiac Devices, Sepsis, UC/Crohn’s Disease, Lupus, Rheumatoid Arthritis, Women’s Health, Phase I-IV Malignant and Non-Malignant Hematology and Solid Tumor studies.